461 related articles for article (PubMed ID: 18000942)
1. Combining fetal nuchal fold thickness with second-trimester biochemistry to screen for trisomy 21.
Borrell A; Mercade I; Casals E; Borobio V; Seres A; Soler A; Fortuny A; Cuckle H
Ultrasound Obstet Gynecol; 2007 Dec; 30(7):941-5. PubMed ID: 18000942
[TBL] [Abstract][Full Text] [Related]
2. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
3. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
[TBL] [Abstract][Full Text] [Related]
4. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21.
Souter VL; Nyberg DA; El-Bastawissi A; Zebelman A; Luthhardt F; Luthy DA
Prenat Diagn; 2002 Mar; 22(3):175-82. PubMed ID: 11920888
[TBL] [Abstract][Full Text] [Related]
5. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
6. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
7. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
8. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
9. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes].
Hu Z; Liu X; Li L; Jia C; Li D; Liu R
Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246
[TBL] [Abstract][Full Text] [Related]
10. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
11. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
12. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
13. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: a seven year review.
Spencer K
Br J Obstet Gynaecol; 1999 Dec; 106(12):1287-93. PubMed ID: 10609723
[TBL] [Abstract][Full Text] [Related]
14. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
15. First-trimester screening for trisomy 21 using alpha-fetoprotein.
Bredaki FE; Wright D; Matos P; Syngelaki A; Nicolaides KH
Fetal Diagn Ther; 2011; 30(3):215-8. PubMed ID: 21952001
[TBL] [Abstract][Full Text] [Related]
16. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
[TBL] [Abstract][Full Text] [Related]
17. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor, and α-fetoprotein.
Huang T; Dennis A; Meschino WS; Rashid S; Mak-Tam E; Cuckle H
Prenat Diagn; 2015 Jul; 35(7):709-16. PubMed ID: 25846403
[TBL] [Abstract][Full Text] [Related]
18. Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
[TBL] [Abstract][Full Text] [Related]
19. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
Spencer K; Crossley JA; Aitken DA; Nix AB; Dunstan FD; Williams K
Ann Clin Biochem; 2003 May; 40(Pt 3):219-31. PubMed ID: 12803832
[TBL] [Abstract][Full Text] [Related]
20. Identification of second trimester screen positive pregnancies at increased risk for congenital heart defects.
Jelliffe-Pawlowski LL; Walton-Haynes L; Currier RJ
Prenat Diagn; 2009 Jun; 29(6):570-7. PubMed ID: 19266536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
